Advice
Following a full submission
Intravenous Ibandronic acid (Bonviva) is accepted for restricted use within NHS Scotland for the treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures. Efficacy on femoral neck fractures has not been established.
Intravenous ibandronic acid is restricted to use in patients who are unsuitable for or unable to tolerate oral treatment options for osteoporosis.
Treatment initiation should be under specialist supervision.
Download detailed advice51KB (PDF)
Medicine details
- Medicine name:
- ibandronic acid, 3mg in 3ml solution for injection (Bonviva)
- SMC ID:
- 301/06
- Indication:
- Osteoporosis in postmenopausal women
- Pharmaceutical company
- Roche
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 September 2006